Omada Health, Inc. (OMDA) fair value analysis
Nasdaq · Updated 2026-10-19
OMDA price how computed
Valuation status
Awaiting full valuationOMDA's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once OMDA's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $17.63
- Sector
- Healthcare
- 12-month range
- $10.94–$26.78
- Market cap
- $1.08B
- From 52-week high
- -34.2%
- Shares outstanding
- 61.2M
- Rank in Healthcare by quality score
- #71 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Omada Health is a digital health company that provides cloud-based platforms and services designed to help individuals manage chronic diseases such as diabetes, hypertension, and behavioral health conditions through coaching, tracking, and personalized interventions. The company operates in the United States, delivering its programs to health plans, employers, and healthcare providers.
OMDA currently ranks #71 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.08B
- P/E (trailing)
- 55x
- Revenue (TTM)
- $310M
- Net margin
- 1.4%
- EPS (TTM)
- $0.32
- Gross margin
- 72.6%
- Revenue growth (3-yr avg)
- 55.6%
- Shares outstanding
- 61.2M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 38 · neutral
- 50-day average
- $21.75
- 200-day average
- $17.52
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05 (post-market)
- Last 6 quarters vs consensus
- 4 beat, 2 missed
- Quarter by quarter
- 2026-06 ▲ beat (+500.0%)
2026-03 ▲ beat (+225.0%)
2025-12 ▲ beat (+440.0%)
2025-09 ▲ beat (+142.9%)
2025-06 ▼ miss (-46.7%)
2025-03 ▼ miss
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 2 hold · 0 sell (12 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $28.4
- Target vs last price
- +61.1%
What our data shows for OMDA
- Our model validated 1 trailing price-to-earnings windows for OMDA, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $10.94–$26.78.
- The 14-day relative strength index sits at a neutral 38.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- OMDA's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the OMDA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — OMDA, a company in the Healthcare sector, showed improvement in TickrTrends' derived indicators this week, with its quality grade rising from C to B. The company's valuation verdict remains awaiting full valuation. No additional changes to other indicators were reported for the week.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — OMDA's 50/200-day trend state shifted from uptrend to mixed this week, indicating a change in the stock's intermediate momentum relative to its longer-term direction. The healthcare sector company remains under awaiting full valuation status according to TickrTrends' derived indicators. This transition from uptrend to mixed suggests investors should monitor whether the stock can maintain its longer-term trajectory or if a broader consolidation phase may be developing.
- 2026-09-21 — TickrTrends' derived indicators for OMDA showed a shift in momentum this week, with the RSI zone moving from oversold to neutral territory. The stock's valuation verdict remains awaiting full valuation, indicating that comprehensive assessment criteria have not yet been fully established or completed.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is OMDA stock undervalued?
OMDA's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is OMDA's TickrTrends verdict?
OMDA is currently marked 'Awaiting full valuation' - a verdict publishes automatically once OMDA's own trailing P/E history validates under our standards.
How does OMDA compare to other Healthcare stocks?
OMDA ranks #71 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is OMDA overbought or oversold?
OMDA's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does OMDA report earnings next?
OMDA's next earnings report is scheduled for 2026-11-05 (post-market), per the published earnings calendar.
Does OMDA usually beat earnings estimates?
Over its last 6 reported quarters OMDA beat the consensus estimate 4 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about OMDA?
Of 12 analysts covering OMDA, 10 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $28.4 (+61.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.